S. Toba

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19

This study shows that combining an oral antiviral with a corticosteroid improves treatment outcomes in delayed SARS-CoV-2 infection in hamsters compared to monotherapy.

2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses

This study identifies 2-thiouridine as a broad-spectrum antiviral against SARS-CoV-2 and other positive-strand RNA viruses by inhibiting viral RNA synthesis.

Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for SARS-CoV-2 3CL Protease

The paper identifies a new class of covalent inhibitors for SARS-CoV-2 3CL protease with chlorofluoroacetamide warhead, showing potent antiviral activity comparable to nirmatrelvir.

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19

This study shows that oral S-217622 reduces SARS-CoV-2 viral load and improves recovery in hamsters, with activity against multiple variants.

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.

SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity

This study shows that SARS-CoV-2 variants with mutations at the furin cleavage site are less virulent and induce protective immunity in hamsters.